Bill Ackman - Pershing Square Capital Management

Taking activist investing up a notch

Name: Bill Ackman
Title: CEO, Pershing Square Capital Management

Last year, Bill Ackman brought activist investing to a whole new level when he teamed up with Valeant Pharmaceuticals ($VRX) on a hostile pursuit of Allergan ($AGN). And while the bid ultimately failed, it's hard to say the takeover fight won't be weighing on directors' minds this year.

For one, Ackman has already made a play for control at another industry player--animal health leader Zoetis ($ZTS). In February, his Pershing Square Capital Management won a seat on the Pfizer ($PFE) spinoff's board for colleague William Doyle after snapping up $1.5 billion in company shares at the end of last year.

Whether he'll attempt to join forces with another potential buyer and get Zoetis sold remains to be seen--and so does whether other activist investors will take a page from his playbook. After all, the strategy raised some eyebrows among regulators and litigation-minded investors who saw shades of insider trading in the partnership.

But either way, his actions may embolden other activist shareholders to stir things up. As EY analysts wrote in a recent report, "shareholder activism is on the rise," and they expect it to be one of the key factors affecting biopharma M&A this year.

As a result, they foresee execs putting more time and effort into shoring up their defenses--whether their companies are rumored targets or not. "You'll see boards and senior management teams giving analysts more respect and trying to get out in front of investors and preempt" the Ackmans out there, report author Jeff Greene told FiercePharma in January. They'll "take their own actions to maximize shareholder value before activists can get involved."

-- Carly Helfand (email | Twitter)

For more:
Special Report: Pharma's top 10 M&A deals of 2014 - Lilly/Novartis Animal Health
Think Allergan CEO's 'all-consuming' Valeant fight won't happen to you? Think again
Report: Activist investor Ackman pushing for Zoetis board positions
Zoetis hikes dividend under continued pressure from activist investor Ackman

Bill Ackman - Pershing Square Capital Management
Read more on

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.